|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
52785611
???header.onlineuser??? :
773
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"calvo"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-06-1 |
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02
|
Levy;Philip, Benjamin;Paz-Ares;Luis, G.;Su;Wu-Chou;Herbert;Scott, M.;Yang;Tsung-Ying;Tolcher;Anthony, W.;Lou;Yanyan;Zenke;Yoshitaka;Cortinovis;Luigi, Diego;Felip;Enriqueta;Domine;Manuel;Sr;Leventakos;Konstantinos;Calvo;Emiliano;Horiike;Atsushi;Pan;Edward;Lin;Daisy;Jia;Xiaoyu;Basak;Priyanka;Chisamore;Jon, Michael;Goto;Yasushi |
| 國立成功大學 |
2024-01-20 |
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
|
Rimassa;Lorenza;Li;Daneng;Ikeda;Masafumi;Yarchoan;Mark;Ryoo;Baek-Yeol;Kossler;Thibaud;Lim;Ho-Yeong;Kwiatkowski;Mariusz;Chang;Ting-Tsung;Kim;Hyun, Jee;Casadei-Gardini;Andrea;Kudo;Masatoshi;Ren;Zhenggang;Calvo;Varela, Maria;Llovet;Josep, M.;Zhang;Yayan;Hatogai;Ken;Siegel;Abby, B.;Cheng;Ann-Lii |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
